drugset / Trial / NCT03649165

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

NCT03649165

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

This study will evaluate bioavailability and food effect of selumetinib (AZD6244) in healthy male participants. A total of 24 healthy male participants will be included to ensure at least 20 evaluable participants. The study is divided in 2 study parts; the same participants will participate in both parts of the study. Part 1 of the study is to investigate the pharmacokinetics (PK) of the selumetinib granule compared to the PK of selumetinib capsule, when administered with water under the fasted conditions. Part 2 of the study is to investigate the PK of selumetinib granule and capsule under fed conditions. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration.

Timeline

Start
2018-09-05
Primary completion
2018-10-21
Completion
2018-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Selumetinib Small molecule 25 mg Oral
Subject Selumetinib Small molecule 50 mg Oral
Background Acetaminophen Small molecule 500 mg